Article, News
Prescient Therapeutics granted US FDA additional Orphan Drug Designation for PTX-100; shares up
Prescient Therapeutics Ltd (ASX:PTX) is trading higher on being granted additional Orphan Drug Designation for PTX-100 for the treatment of T-cell lymphomas (TCL), including cutaneous TCL (CTCL)….
Article, News
Prescient Therapeutics provides PTX-100 trial update, readies for investor briefing
Since the last trial update, a patient with relapsed peripheral T cell lymphoma reported a partial response, meaning the size of the cancer tumour has…
Article, News
Prescient Therapeutics PTX-100 continues to exhibit excellent safety profile
Prescient’s PTX-100 Phase 1b study shows encouraging responses on a patient population that is notoriously difficult to treat. Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has revealed…
Article, News
Prescient Therapeutics’ PTX-100 expansion cohort continues to deliver on safety and clinical movement
Prescient Therapeutics Ltd (ASX:PTX) continues to demonstrate a favourable safety profile with its PTX-100 Phase 1b expansion cohort targeting relapsed and refractory T cell lymphoma (TCL) – and…
Article, News
Prescient Therapeutics A$2.5 million top-up placement brings raise total to A$11.3 million
Prescient Therapeutics Ltd (ASX:PTX) has brought in another A$2.5 million in a top-up placement to cater for strong investor demand. Late last week, the clinical-stage oncology…
Article, News
Prescient Therapeutics exceeds SPP target, delivers top-up placement to accommodate demand
“It is a significant achievement to exceed our target amidst challenging market conditions,” said managing director and CEO Steven Yatomi-Clarke.
Article, News
Prescient Therapeutics unveils novel adjuvant for enhancing cellular immunotherapy: CellPryme-A
CellPryme-A is the latest in a portfolio of platform cell technologies that can not only create innovative programs for Prescient, but are also enabling technologies…
News
Prescient Therapeutics to unveil CellPryme-A platform at CAR-TCR summit in Boston
Prescient Therapeutics Ltd (ASX:PTX) has been invited to present two sessions at the upcoming CAR-TCR Summit in Boston on September 19 to 22, during which the…
News
Prescient Therapeutics hails collaboration with MD Anderson Cancer Center for blood cancer therapy
Prescient Therapeutics Ltd (ASX:PTX) CEO and managing director Steven Yatomi-Clarke chats with Andrew Scott from Proactive about the company’s strategic collaboration agreement with the University of Texas MD…
Article, News
Prescient Therapeutics to collaborate with largest cancer centre in the US to develop blood cancer treatment
“We believe that OmniCAR is a transformational platform for cellular immunotherapy, and we look forward to testing the potential of this promising TCR-like binder for…
RECENT POSTS
Categories
- Article (102)
- Media (6)
- News (295)
- Uncategorized (1)
- Webcast Video (7)